الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

mylan institutional llc - methotrexate (unii: yl5fz2y5u1) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hospira, inc. - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin's lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection

نيوزيلاندا - الإنجليزية - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - methotrexate 100 mg/ml - concentrate for injection - 100 mg/ml - active: methotrexate 100 mg/ml excipient: sodium hydroxide water for injection - antineoplastic chemotherapy. methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of medicine induced remissions. high dose therapy. in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy. methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatological consultation.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

teva parenteral medicines, inc. - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy regimen. methotrexate injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. methotrexate injection is indicated for the treatment of adults and pediatric patients with non-hodgkin lymphoma. methotrexate injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single-agent. methotrexate injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (gtn) as part of a combination chemotherapy regimen. methotrexate injection is indicated for

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

accord healthcare, inc. - methotrexate (unii: yl5fz2y5u1) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy regimen. methotrexate injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. methotrexate injection is indicated for the treatment of adults and pediatric patients with non-hodgkin lymphoma. methotrexate injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single-agent. methotrexate injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (gtn) as part of a combination chemotherapy regimen. methotrexate injection is indicated for

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - methotrexate (unii: yl5fz2y5u1) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate injection is indicated for the treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy regimen. methotrexate injection is indicated for the prophylaxis and treatment of meningeal leukemia in adult and pediatric patients. methotrexate injection is indicated for the treatment of adults and pediatric patients with non-hodgkin lymphoma. methotrexate injection is indicated for the treatment of adults and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with breast cancer as part of a combination chemotherapy regimen. methotrexate injection is indicated for the treatment of adults with squamous cell carcinoma of the head and neck as a single-agent. methotrexate injection is indicated for the treatment of adults with gestational trophoblastic neoplasia (gtn) as part of a combination chemotherapy regimen. methotrexate injection is indicated for

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

physicians total care, inc. - methotrexate (unii: yl5fz2y5u1) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - methotrexate disodium - oral solution - 2 mg/ml - methotrexate - antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues - it is indicated in the following oncological indications: the maintenance treatment of acute lymphocytic leukaemia (all) in children and adults; the treatment of malignant trophoblastic tumours and for the treatment of severe active rheumatoid arthritis in adults and the treatment of severe forms of psoriasis vulgaris including chronic plaque psoriasis, erythrodermic psoriasis, psoriatic arthritis and pustular psoriasis which are not responsive to other conventional therapies such as phototherapy, puva and retinoids.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - methotrexate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - antineoplastic chemotherapy - methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy - in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box) - methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - methotrexate, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - antineoplastic chemotherapy - methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy - in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box) - methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.